Improvement of type 2 diabetes mellitus control with hydroxychloroquine added to triple oral antidiabetis drugs: a case report
Abstract
Hydroxychloroquine, an antimalarial drug has also been found to possess antidiabetic action. It inactivates insulin degradation enzymes and also delays the dissociation of insulin from the insulin receptor thus also lowering the insulin resistance and increasing insulin sensitivity. Here we report a case of a male patient with uncontrolled type 2 diabetes mellitus (T2DM) who obtained a better glycemic control when hydroxychloroquine was added to the existing pharmacotherapy. The patient has been taking metformin, glimepiride and acarbose for the last 2 years but his diabetes was poorly controlled with glycated haemoglobin (HbA1c) of 9.6%. Patient was proposed to intensify the treatment with insulin however he refused it. He was subsequently prescribed hydroxychloroquine 400 mg. Patient responded well to the therapy of hydroxychloroquine and subsequent follow-ups showed good glycaemic control. (Clin Diabetol 2017; 6, 6: 211–214)
Keywords: type 2 diabetes mellitushydroxychloroquineoral hypoglycemic agents
References
- Wu Y, Ding Y, Tanaka Y, et al. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014; 11(11): 1185–1200.
- Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice. 1995; 28(2): 103–117.
- Kaplan YC, Ozsarfati J, Nickel C, et al. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016; 81(5): 835–848.
- Emami J, Gerstein HC, Pasutto FM, et al. Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol. 1999; 77(2): 118–123.
- SMITH G, CHRISTENSEN J, RIDEOUT J, et al. Hepatic processing of insulin. Characterization of differential inhibition by weak bases. European Journal of Biochemistry. 1989; 181(2): 287–294.
- Wasko MC, McClure CK, Kelsey SF, et al. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015; 58(10): 2336–2343.
- Mercer E, Rekedal L, Garg R, et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012; 14(3): R135.
- Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007; 298(2): 187–193.
- Gerstein HC, Thorpe KE, Taylor DW, et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. Diabetes Res Clin Pract. 2002; 55(3): 209–219.
- Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014; 30(7): 1257–1266.
- Padsalge M, Abhyankar M, Ghag S. Insulin sparing effect of hydroxychloroquine in uncontrolled diabetes mellitus. Clinical Diabetology. 2016; 5(4): 138–140.
- Bennett M. Antimalarials in dermatology. Current Problems in Dermatology. 2000; 12(6): 257–259.
- Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003; 110(7): 1321–1326.
- Marmor MF, Kellner U, Lai TYY, et al. American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016; 123(6): 1386–1394.